Combodart reduces prostate volume and, therefore, causes a decrease in serum PSA levels by approximately 50% after 6 months in patients with BPH.
Patients receiving Combodart should have a new PSA baseline established after 6 months of treatment. It is recommended to monitor PSA values regularly thereafter.
Any confirmed increase from lowest PSA level while on Combodart should be carefully evaluated as it may signal the presence of prostate cancer or non-compliance to therapy with Combodart.
PSA levels in BPH patient receiving Combodart (schematic representation):
Treatment with dutasteride does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established. 
Additional checks on treatment compliance or other factors that can affect PSA values should be considered in the interpretation of results.
Please refer to the SPC for full information on how to monitor PSA levels in patients receiving Combodart.
* Prostate-Specific Antigen